... in Phase III and vitiligo, and vitiligo is one of the disease where today, there is no medicine approved. And obviously, it will be the first of its kind to have a disease-modifying effect, if approved, and it's a form of a topical JAK and a number of other programs where we made a lot of progress. On the right is the size of our revenue of $2.5 billion more or less in 2020, growing at around 20%. And as you can see, coming from research that was done in-house and products that we have developed ourselves. Now when we look at 2021, obviously, we have a number of approvals that are subsequent to the submission we did last year. There are 7 of them. We already received approval for pemigatinib in cholangiocarcinoma in Japan and Europe, and we are now in the process, hopefully, of getting approval for RUX cream in atopic dermatitis, for retifanlimab, an antibody against PD-1 and Jakafi in chronic GVHD in the U.S. and the tafasitamab Monjuvi...
